Reid Robison, acquiring his two businesses, the Cedar Psychiatry network of clinics and Cedar Clinical Research, a contract research organization. The company partnered with psychiatrist Dr. We set out to build a company focused on the clinic and clinical research site, the places where people were going to have these experiences," Conforti explained. "Our investment thesis was, in short, to find the people that are treating people with these innovative modalities today, in jurisdictions where it's legal, and partner with them and support them. "We saw the data coming out of Johns Hopkins and Imperial College and understood very quickly that there was a model of care there that was innovative and different from the standard of care," Conforti told Streetwise Reports. (NM:CSE) was founded in 2019 by CEO Yaron Conforti and two partners. Food and Drug Administration (FDA) approved esketamine nasal spray (Spravato) for treatment-resistant depression.
Johns Hopkins University and Imperial College London have both set up psychedelic research centers, and ketamine infusions are now being used as treatments for depression, eating disorders, anxiety, PTSD and other conditions. The last few years has seen a major shift in attitudes on psychedelic drugs, as they have moved from fringe to the subject of serious study by respected medical institutions.
0 kommentar(er)
